Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia

Ido Weinberg, Xiaokui Gu, Jay Giri, Soo E. Kim, Michael J. Bacharach, Bruce H. Gray, Barry T. Katzen, Alan H. Matsumoto, Yung-wei Chi, Kevin R. Rogers, James Froehlich, Jeffrey W. Olin, Heather L. Gornik, Michael R. Jaff

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Fibromuscular dysplasia (FMD), a non-inflammatory arterial disease, may lead to renovascular hypertension (HTN) and cerebrovascular disease. Little is known about medication use in FMD. Clinical features and medication use were reviewed in a national FMD registry (12 US sites). Medication usage was assessed in raw and adjusted analyses. Covariates included demographic characteristics, co-morbid conditions and vascular bed involvement. A total of 874 subjects (93.6% female) were included in the analysis. Mean age was 55.6±13.1 years, 74.5% had HTN, 25.4% had a history of transient ischemic attack or stroke, and 7.5% had a history of coronary artery disease (CAD). Renal and cerebrovascular arteries were affected in 70.4% and 74.7%, respectively. Anti-platelet agents were administered to 72.9% of patients. In multivariate analyses, factors associated with a greater likelihood of anti-platelet agent use were older age (OR=1.02 per year, p=0.005), CAD (OR=3.76, p=0.015), cerebrovascular artery FMD involvement in isolation (OR=2.31, p

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalVascular Medicine (United Kingdom)
Volume20
Issue number5
DOIs
StatePublished - Oct 1 2015

Keywords

  • anti-platelet
  • fibromuscular dysplasia
  • FMD
  • hypertension
  • medication

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia'. Together they form a unique fingerprint.

  • Cite this

    Weinberg, I., Gu, X., Giri, J., Kim, S. E., Bacharach, M. J., Gray, B. H., Katzen, B. T., Matsumoto, A. H., Chi, Y., Rogers, K. R., Froehlich, J., Olin, J. W., Gornik, H. L., & Jaff, M. R. (2015). Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia. Vascular Medicine (United Kingdom), 20(5), 447-453. https://doi.org/10.1177/1358863X15584982